This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Rhodiola
Rhodiola rosea is the best-evidenced adaptogen for fatigue resistance and mental performance under stress — a Crassulaceae root that the Russians and Scandinavians have been studying for 60+ years …
Aliases (8)
Overview
What is Rhodiola?
Rhodiola (Rhodiola rosea, "golden root" or "arctic root") is a flowering plant native to cold regions of Europe and Asia, used in traditional Russian and Scandinavian medicine as an adaptogen. The root extract is standardized to rosavins and salidroside.
Key Benefits
Reduces stress-related fatigue, improves mental performance under sustained stress, and modulates mood and burnout symptoms. Some evidence for use in mild-to-moderate depression, athletic endurance, and altitude tolerance; effects are typically subtle and chronic.
Mechanism of Action
Salidroside and rosavins modulate the HPA axis (reducing cortisol reactivity to stress), inhibit MAO-A and MAO-B, and modulate serotonin, dopamine, and norepinephrine signaling. Activate AMPK and Nrf2 antioxidant pathways.
Peptide Interactions
Different mechanism (rhodiola = monoaminergic; caffeine = adenosine antagonist) → additive lift without doubling cardiovascular load. 200 mg rhodiola + 100-2…
Smooths any rhodiola stimulation; covers the ~15-20% jitter-sensitive subset.
Compatible. Rhodiola covers HPA-axis stress component; modafinil hits histamine/orexin. No mechanistic overlap; clinical reports support synergy. No serotoni…
Opposite adaptogen profile — rhodiola = pro-energy AM; ashwagandha = anxiolytic/cortisol PM. Logical AM/PM pairing. No mechanism conflict.
Different adaptogen class (BDNF/cholinergic vs monoamine/HPA). Sometimes combined for "comprehensive adaptogen" stacks; no contraindication.
Tyrosine is the dopamine precursor; rhodiola mildly inhibits MAO-A → both push the dopamine arm of the stress response. Useful under acute high-cognitive-loa…
Neutral but commonly co-stacked; combined endurance + cognitive evidence base for resistance-trained users (Koozehchian 2025 was creatine-naive but the popul…
Antioxidant convergence; rhodiola's NRF2 activation complements direct antioxidants.
Theoretical additive monoamine effect — rhodiola's mild MAO-A inhibition could compound. Hard block.
Serotonin-syndrome theoretical signal. Clinical risk is low (Mao 2015 used rhodiola alongside sertraline-comparator with no AEs) but monitor for tremor, hype…
Additive sympathetic load; usually not dangerous but uncomfortable.
Likely fine — MAO-B vs MAO-A is the relevant axis. At doses >10 mg/day where selegiline loses selectivity, treat as MAOI.
What to Expect
- Onset30-90 min. Tmax for salidroside ~1 hr; salidroside has 32-98% oral bioavailability depending on extract quality and fed/fasted state (per community-data blo…
- Peak2-4 hours. Subjectively a background lift, not a stimulant rush — closer to "I forgot I was tired" than "I'm wired."
- TaperGradual; rhodiola has multiple active metabolites with effective half-lives 3-8 hr depending on the constituent. By ~10-12 hr post-dose it's gone.
Side Effects & Safety 7
Side Effects
- 1Generally none significant at therapeutic doses (100-400 mg). This is one of rhodiola's biggest pharma advantages.
- 2Mild stimulation / jitter in the ~15-20% stim-sensitive subset — manageable by dose-splitting or extract switch.
- 3Insomnia if dosed late afternoon or evening (the most common avoidable issue)
- 4Mild GI upset — gas, mild nausea on empty stomach; resolves with food
- 5Headache — uncommon; usually dose-related (>500 mg) and resolves on dose reduction
- 6Dry mouth
- 7Vivid dreams — anecdotal but reported; consistent with mild monoamine modulation
When to Stop
- No serious adverse events documented in trial literature across the entire published rhodiola RCT base (Hung 2011 meta-analysis: zero serious AEs across 11 trials).
- Bipolar mania precipitation: Rare case reports of manic episodes in bipolar patients taking rhodiola. Mechanism is consistent (mild monoamine activation in a population sensitive to manic switch). Hard contraindication if known bipolar diagnosis — already coded as hard-block in fit-criteria.
- MAOI interaction (theoretical → clinical): Mild MAO-A inhibition could compound with non-selective MAOI antidepressants (phenelzine, tranylcypromine). No documented hypertensive crises in the literature but the mechanism is real — HARD BLOCK in MAOI users.
- Allergic reactions — exceptionally rare; isolated case reports of urticaria.
- Weeks 1-2: Sleep-onset disruption signal. If sleep latency increases >20 min, move dose earlier in the day or reduce to 100 mg.
- First 4 weeks of higher dose (>300 mg): Monitor for stim-subset signals — anxiety, palpitations, jitter. Drop dose if persistent.
- Bipolar-spectrum mood watch: Any user with first-degree family history of bipolar — track mood for 8 weeks at minimum. Stop if cycling, hypomania, or sleep-need reduction emerges.
References
Darbinyan et al. 2000 — Rhodiola in night-shift physicians (Phytomedicine 7(5):365-71, PMID 11081987)
foundational shift-work/cognitive-under-stress RCT, n=56, SHR-5 170 mg/day × 2 weeks crossover.
View StudySpasov et al. 2000 — Rhodiola in stressed medical students (Phytomedicine 7(2):85-9, PMID 10839209)
exam-stress RCT, n=40, SHR-5 100 mg BID × 20 days; significant improvements across cognitive and physical endpoints.
View StudyOlsson et al. 2009 — Rhodiola in stress-related fatigue/burnout (Planta Med 75(2):105-12, PMID 19016404)
cleanest burnout RCT, n=60, SHR-5 576 mg/day × 28 days; significant improvement on Pines burnout scale and cortisol awakening response.
View StudyEdwards et al. 2012 — Rhodiola WS 1375 in life-stressed adults (Phytother Res 26(8):1220-5, PMID 22228617)
open-label, n=101, 200 mg BID × 4 weeks; rapid-onset signal (3 days).
View StudyMao et al. 2015 — Rhodiola vs sertraline vs placebo for MDD (Phytomedicine 22(3):394-9, PMID 25837277)
n=57, 12 weeks; less efficacy than sertraline but 50% fewer adverse events; supports gentle first-line in mild-moderate depression.
View StudyHung et al. 2011 — Meta-analysis of Rhodiola for physical and mental performance (Phytomedicine 18(4):235-44, PMID 21036578)
11 RCTs; "may have beneficial effects" with replication caveat.
View StudyTinsley et al. 2023 — Rhodiola rosea as adaptogen for exercise performance review (Br J Nutr 131(3):461-473, PMID 37641937)
16 human trials, 363 participants; effect non-unanimous, dose/extract heterogeneity dominant.
View StudyWang et al. 2025 — Rhodiola rosea endurance meta-analysis (Front Nutr 12:1645346, Sep 2025)
26 RCTs; significant VO2max, time-to-exhaustion, antioxidant, muscle-damage improvements; dose-response above 600 mg/day.
View StudyKoozehchian et al. 2025 — Dose-response Rhodiola for resistance performance + cognition (Nutrients 17(23):3736, PMID 41374026)
n=27 resistance-trained, 200 mg or 1500 mg × 7 days crossover; bench-press strength, reps, total volume, Stroop all improved at both doses.
View StudyMarcos-Frutos et al. 2025 — Rhodiola for bench-press/bench-pull under mental fatigue (Nutrients 17(6):940)
n=18 resistance-trained crossover, triple-blinded, Rhodiozen extract; increased bench-press reps and bench-pull velocity, including under mental-fatigue condition.
View StudyLatest research
- rctDose-response Rhodiola rosea on anaerobic exercise + cognition (Koozehchian 2025)7-day loading at 200 mg/d or 1500 mg/d in 27 resistance-trained adults improved bench-press strength, reps-to-failure, and Stroop executive function; minimal effect on anaerobic cycling. Both doses worked — supports the low end (200 mg) is sufficient for resistance-trained users.
- meta-analysisRhodiola rosea endurance meta-analysis — 26 RCTs (Wang 2025 Front Nutr)Pooled 26 RCTs — significant improvement in VO2max, time-to-exhaustion, time-to-peak; reduced muscle damage and improved antioxidant markers. Doses >600 mg/day produced larger VO2max gains. No effect on IL-6 / CRP.
- rctMarcos-Frutos 2025 bench-press / bench-pull crossover RCTn=18 resistance-trained (Rhodiozen extract) — increased bench-press reps and faster bench-pull velocity vs placebo, including under mental-fatigue condition. Adds 2025 strength-performance signal to the mostly-endurance literature.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.